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ABSTRACT
Cyclin E supports pre-replication complex (pre-RC)
assembly, while cyclin A-associated kinase acti-
vates DNA synthesis. We show that cyclin E, but
not A, is mounted upon the nuclear matrix in
sub-nuclear foci in differentiated vertebrate cells,
but not in undifferentiated cells or cancer cells. In
murine embryonic stem cells, Xenopus embryos and
human urothelial cells, cyclin E is recruited to the
nuclear matrix as cells differentiate and this can
be manipulated in vitro. This suggests that pre-RC
assembly becomes spatially restricted as template
usage is defined. Furthermore, failure to become re-
stricted may contribute to the plasticity of cancer
cells.
INTRODUCTION
Cyclin E is a G1 cyclin that associates preferentially with
cyclin-dependent protein kinase 2 (CDK2). There are two
mammalian E type cyclins, with similar expression,
function and structure in complex with CDK2 (1).
Cyclin E rises in mid G1, peaks after passage through
the restriction point (R), and falls around G1/S (2).
Initiation of mammalian DNA replication is controlled
by CDK2, which, in association with cyclins E and A,
acts on proteins that assemble at replication origins.
Cyclin E plays a role in pre-replication complex
(pre-RC) formation in higher eukaryotes, cooperating
with CDC6 and CDT1 to support assembly of the mini
chromosome maintenance (MCM) complex (3–7). Cyclin
E is also required for centrosome duplication (8), where its
role also appears to be distinct from that of cyclin A (3,9).
Despite increasingly well-deﬁned roles for cyclin E,
ﬁbroblasts isolated from mice deﬁcient in E1 and 2 are
able to proliferate, indicating that cyclin E is redundant
in the mitotic cell cycle. In fact, cyclin E appears to be
essential for MCM assembly only in cells preparing for
S phase that is not preceded by mitosis, such as
those re-entering cycle from G0 or undergoing
endoreduplication (5,10). By contrast, CDK2-deﬁcient
ﬁbroblasts do not encounter similar problems (11), sug-
gesting that cyclin E may act independently of CDK2
under some circumstances. Consistent with this, a
kinase-deﬁcient mutant partially corrects the phenotype
of cyclin E null cells, restoring MCM complex assembly
(12). Similarly, the centrosomal function of cyclin E may
also be CDK2 independent (8). Thus, while CDK2 is the
preferred binding partner of cyclin E and cyclin E can
clearly activate CDK2, evidence points to additional
CDK-independent roles for cyclin E.
DNA replication is constrained in nuclear space to
discrete sub-nuclear foci that are associated with a
non-chromatin protein/RNA structure, that is deﬁned
as ‘nuclear matrix’ or ‘nucleoskeleton’, and can be
visualized by electron microscopy (13,14). Nuclear
matrix-associated DNA is enriched with replication
origins during G1 phase, suggesting that recruitment
plays a role in initiation (15), while the pre-RC proteins
CDC6 and ORC1 both undergo transient association in
mammalian cells (16). However, there is little evidence to
indicate at what point in pre-RC assembly DNA replica-
tion origins are recruited, or what the nuclear
matrix-associated receptors might be.
In Xenopus egg extracts cyclin E is reported to bind to
chromatin, most likely via CDC6, which acts as a
chromatin-associated receptor (4). Similarly, work with
mouse embryonic ﬁbroblasts and HeLa cells indicates
that cyclin E is loaded onto chromatin and that this
involves direct interaction with both CDT1 and MCM
proteins (12). Thus, immobilization of cyclin E appears
to occur in association with pre-RC formation and the
prevailing view is that this reﬂects association with chro-
matin. However, the protocols used in most of these
studies do not discriminate between chromatin and
nuclear matrix, and the picture is further complicated by
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and pathological state.
Here we show that (i) cyclin E is immobilized in the
nucleus by association with the nuclear matrix, (ii) that
recruitment occurs as cells differentiate and (iii) that
cyclin E is not attached to the nuclear matrix in cancer
cells. This is the ﬁrst time that either of the
replication-associated cyclins has been linked with the
nuclear matrix. These novel ﬁndings point to an important
role for cyclin E in genome organization. They also argue
that despite the relative ease with which cancer cells can be
manipulated, they are a questionable choice for analysis of
nuclear matrix function or the spatial organization of
DNA replication.
MATERIALS AND METHODS
Cell culture
Cell lines were sourced from JCRB or ATCC and main-
tained as recommended. Mouse cardiac ﬁbroblasts ex-
pressing Col1A1 (not shown) were derived from atria
dissected from a C57/BL6 mouse heart. Mouse ES cells
(KES1) were differentiated to embryoid bodies or
embryoid body outgrowths as described (17). Xenopus
laevis embryos were produced as described (18). NHU
cells were established from surgical samples collected
with ethical review and informed patient consent and
induced to differentiate as described (19). NIH3T3 cells
were synchronised and labelled with Bromodeoxyuridine
(BrdU) as described (3).
Nuclear fractionation
Nuclear fractionation was carried out as described (20).
Typically, 25% of cell lysate in CSK buffer was removed
(total) and the rest a diluted 2-fold with CSK, 0.2% Triton
X-100 and separated by centrifugation into detergent
supernatant (SN) and pellet (P). Pellet was resuspended
in CSK with 0.5 M NaCl to produce salt wash or ‘w’.
Pellet was further re-suspended in digestion buffer and
incubated with or without DNase 1 (Roche), supple-
mented with 0.5 M NaCl and separated by centrifugation.
Cell equivalents of each fraction were analysed by western
blot. Mouse cyclin E was detected with rabbit polyclonal
antibody 07-687 (Upstate) in Figure 1B and F, and
veriﬁed with ab7959 (not shown); and with ab7959
(Abcam) in Figures 1C and 3A. Human cyclin E was
detected with mouse monoclonal antibody sc247 HE12
(Santa Cruz). Xenopus cyclin E was detected with a
rabbit polyclonal antibody that was a kind gift from
Figure 1. Cyclin E is present in nuclear matrix-associated foci. (A) Immunoﬂuorescent detection of cyclin E (green) and DNA (blue) in cycling
NIH3T3 cells after extraction with or without DNase. Bar is 5mm. Histogram shows average ﬂuorescence intensity derived from multiple images with
SEM. (B) Western blot showing cyclin E and other proteins as indicated, in fractions generated by serial extraction of NIH3T3 cells. T=total
protein. Cells were lysed in detergent containing buffer to generate pellet (P) and supernatant (SN). Pellet was washed with 0.5 M NaCl to generate
‘w’ and extracted with or without DNase. All fractions are derived from cell equivalents. (C and D) As in B, showing cyclin E in early passage
murine cardiac ﬁbroblasts and human lung cell line HFL1, respectively. (E) The proportion of NIH3T3 cells engaged in DNA synthesis between 14
and 19 h after release from quiescence, measured by incorporation of BrdU. Inset shows BrdU (red) in nuclei (blue) at 19 h. (F) Western blots
showing total cyclin E, CDC6 and histone H3 14–19 h after release from quiescence (upper panel). After extraction with DNase cyclin E remained in
the pellet (middle panel), despite complete release of histone H3 (lower panel), at all time points.
2672 Nucleic Acids Research, 2011,Vol.39, No. 7Tim Hunt. Cyclin A was detected with C4710 (Sigma),
CDK2 with 7954-1 (Abcam), CDC6 with sc9964 (Santa
Cruz), lamin B2 with E3 (invitrogen) and histone H3 with
1791 (Abcam).
Immunoﬂuorescence
Cells on coverslips were washed in PBS and CSK, 0.1%
Triton X-100 (detergent washed). For DNase 1 treatment,
coverslips were washed as above with digestion buffer plus
DNase 1 and incubated at 25C for 45min. Cells were
ﬁxed in 4% paraformaldehyde for 20min and blocked
with antibody buffer (10% BSA, 0.02% SDS, 0.1%
Triton X-100 in PBS). Human cyclin E was detected
with mouse monoclonal antibody sc247 HE12 (Santa
Cruz) and mouse cyclin E with E4 (Santa Cruz). DNA
was counterstained with Hoechst 33258 (Sigma). Images
were collected using a Zeiss Axiovert 200 M and Openlab
image acquisition software. Fluorescence intensity was
quantiﬁed from raw images acquired under identical
imaging parameters.
Gene expression
RNA was extracted using Trizol (Ambion) and
reverse-transcribed with SuperScript III (Invitrogen).
Primers and probes for quantitative RT–PCR are given
in Supplementary Table S2. GAPDH was used to normal-
ize results, which are expressed as relative quantiﬁcation
(RQ).
RESULTS AND DISCUSSION
In murine NIH3T3 cells, cyclin E resists extraction with
DNase despite efﬁcient extraction of the majority of
nuclear DNA and is located within punctate nuclear foci
(Figure 1A). Thus, cyclin E is associated with
nuclease-resistant, non-chromatin nuclear structures that
are consistent with the nuclear matrix. Analysis of protein
fractions generated by sequential extraction with deter-
gent, salt and nuclease conﬁrm that none of the
immobilized cyclin E is released by DNase, despite
release of more than half of the histone H3. Lamin B1,
a nuclear protein, predicted to fractionate with the nuclear
matrix, is detected in the DNase pellet fraction, conﬁrm-
ing the validity of the fractionation protocol (Figure 1B,
lanes 5 and 6). Similar results were obtained with other
differentiated cells, including primary murine cardiac
ﬁbroblasts (Figure 1C), human lung cell line HFL1
(Figure 1D), in vitro differentiated mouse embryonic
stem cells and normal human urothelial (NHU) cells (see
later). Four independent cyclin E antibodies gave similar
results (not shown). Therefore, immobilization of cyclin E
on the nuclear matrix occurs in primary and established
cell lines of both human and murine origin. Under the
same conditions we did not detect CDK2 or cyclin A in
the nuclear matrix fraction (Figure 1B) and there have
been no other reports of nuclear matrix-association for
either cyclin E or cyclin A. Therefore, although both
cyclins have been localized to sub-nuclear foci (21), our
analysis suggests that cyclins E and A undergo fundamen-
tally different types of interaction.
NIH3T3 cells synchronised by release from quiescence
pass through R after 15 h and enter S phase at 18–19 h
(3) (Figure 1E). Cyclin E protein levels remained similar
throughout this period, while CDC6 expression increased
between 14 and 15 h, indicating passage through R
(Figure 1F). Throughout, cyclin E remained resistant to
high salt (not shown) and DNase (Figure 1F), suggesting
that its association with the nuclear matrix is not regulated
during passage through R, or entry to S phase.
Much of the evidence identifying cyclin E as
chromatin-associated protein stems from analysis of
activated Xenopus egg extracts that contain cyclin E but
little DNA or nuclear structure on which to bind, or from
cancer cells, usually HeLa cells. Consistent with the pre-
vailing view, our analysis indicates that cyclin E is not
DNase resistant in embryonic and undifferentiated
lineages, or in cancer cells (Figure 2 and Supplementary
A
B
Figure 2. Cyclin E is not immobilized on the nuclear matrix in cancer
cells. (A) Western blot showing absence of cyclin E from the DNase
resistant fraction in representative cancer cell lines fractionated by the
procedure used in Figure 1. (B) Immunoﬂuorescence images of RT4
cells showing cyclin E (green) and DNA (blue). Cyclin E occupies a
focal pattern in mock treated cells, but is fully extracted by DNase.
Bar is 5mm.
Nucleic Acids Research,2011, Vol.39, No. 7 2673Table S1). In some cases, such as the prostate cancer line
LNCAP or the urothelial cancer line RT4, cyclin E resists
extraction with detergent (Figure 2A), but in all but one of
the eight cancer cell lines we studied cyclin E was not re-
sistant to DNase and is therefore not mounted on the
nuclear matrix. Notably, cyclin E remained organized
into sub-nuclear foci (Figure 2B), showing that attach-
ment to an underlying architecture is not required to
specify foci.
To reconcile these two sets of observations and test
whether both states are in fact encountered in vivo,w e
used three different experimental systems. These yielded
consistent results and show clearly that recruitment to the
nuclear matrix is established as cells differentiate.
In undifferentiated murine embryonic stem (ES) cells
the majority of cyclin E was not resistant to DNase
(Figure 3A, lane 2 upper panels), but shifted into the
DNase-resistant fraction (lane 4, lower panels) upon in-
duction of differentiation (17). Reduced OCT4 and
increased GATA4 expression conﬁrmed endodermal dif-
ferentiation (Figure 3B), although markers for other
lineages were also present (not shown). Similar results
were obtained with X. laevis embryos during development
from fertilized egg to tadpole. The embryo is transcrip-
tionally silent until the mid blastula transition (MBT)
when zygotic transcription begins in a process that
involves chromatin remodelling and reorganisation of rep-
lication origins (22). Prior to the MBT (embryo stages 2
and 8, Figure 3C), cyclin E was fully solubilised by deter-
gent (Figure 3D), while after the MBT (stages 10 and 39) a
resistant fraction of cyclin E was evident. Further analysis
showed that in gastrulating embryos (stage 10), this was
Figure 3. Cyclin E is recruited to the nuclear matrix during embryonic stem cell differentiation and Xenopus laevis development. (A) Western blot
showing protein fractions derived from murine ES cells before and after embryoid body formation, and after 25 days in culture under differentiation
conditions. Images show cell populations before extraction. Bar=50mm. Cyclin E changes from detergent soluble in ES cells and embryoid bodies to
mostly DNase resistant in differentiated cells despite efﬁcient extraction of histone H3. (B) Quantitative RT–PCR of differentiation markers Oct4 and
GATA4 in cells in A, with SEM. (C) Xenopus embryos at stages 2, 8, 10 and 39. (D) Western blots showing total cyclin E and the proportion that is
detergent-resistant (P) and detergent soluble (SN) at each stage. (E) Western blot showing detergent-resistant cyclin E after further incubation
without (mock) or with DNase. Histone H3 was used to control for chromatin digestion. By stage 39 the detergent resistant fraction of cyclin E is
DNase resistant.
2674 Nucleic Acids Research, 2011,Vol.39, No. 7released by DNase (Figure 3E), while in the tadpoles
(stage 39) it was completely resistant (lane 1). Therefore,
cyclin E is recruited to the nuclear matrix during Xenopus
development. If cyclin E recruitment is interpreted as a
surrogate for replication origin recruitment, the data
imply that this occurs sometime after the MBT. The
matrix-association of some key housekeeping genes, such
as the rRNA genes, is reorganised at the MBT as they
become activated. Others such as the keratin domain,
which encodes genes expressed only in adult keratinocytes,
are not speciﬁed until later in development (23). Thus the
formation of functional links with the nuclear matrix may
be a staged process that occurs as template usage is
deﬁned.
Complementary analysis in a well-characterised model
of urothelial cell differentiation (19), revealed a similar
picture. In undifferentiated cycling and conﬂuent popula-
tions of NHU cells (Figure 4A) cyclin E was fully
A
B
DE
C
Figure 4. Recruitment of cyclin E to the nuclear matrix during differentiation of NHU cells (A) Cycling NHU cells were grown to conﬂuence with-
out differentiation or induced to differentiate over 7 days. (B) Cyclin E (green) and DNA (blue) in nuclei from cycling cells (Day 1, upper panels),
differentiated (Day 7, middle panels) and conﬂuent control cells (Day 7, lower panels), after extraction with detergent or DNase as indicated. Bar is
10mm. (C) Detergent and DNase extracted protein fractions from the populations shown in A. Cyclin E changes from DNase sensitive in undifferen-
tiated NHU and conﬂuent control cells to partly DNase resistant in differentiated NHU cells, despite efﬁcient extraction of histone H3. (D) Quantitative
RT-PCR showing uroplakin 2 expression with SEM. (E) Model of cyclin E foci (green) associated with chromatin (blue background), unconstrained
by attachment to the nuclear matrix (gray lines) in undifferentiated cells, but mounted upon a nuclear matrix in differentiated cells.
Nucleic Acids Research,2011, Vol.39, No. 7 2675extracted with DNase (Figure 4B and C, upper and lower
panels). However in cells induced to differentiate, approxi-
mately half of the cyclin E was recruited to the nuclear
matrix (Figure 4B and C, middle panels). The transition to
differentiated urothelium was veriﬁed visually (Figure 4A)
and by analysis of uroplakin 2 expression (Figure 4D).
These analyses in three diverse differentiating systems
show that cyclin E is a conditional nuclear matrix protein
that is recruited during differentiation and imply a
conserved matrix-associated function. We propose that
recruitment to the nuclear matrix reﬂects changes in the
location at which cyclin E executes its function in pre-RC
assembly, and that this switches from being unconstrained
in nuclear space in undifferentiated cells, to being speciﬁed
by immobilization on an underlying nuclear architecture
(Figure 4E), potentially restricting the genome to cell
type-speciﬁc patterns of DNA replication.
Attachment of DNA to the nuclear matrix occurs via
sequences that anchor the genome in loops, while add-
itional transient associations are thought to give rise to
loops that are reeled through factories as DNA replicates
(24). Changes in loop size have been observed directly and
linked to transcriptional and developmental decisions,
suggesting that their selection may contribute to restric-
tion of gene expression and limit the plasticity of
differentiating cells compared to stem and progenitor
cells. Remodelling of attachments and establishment of
replicon size occurs during passage through mitosis in
Xenopus (25), but little is known about how pre-RCs are
recruited to the matrix. Moreover, in the absence of a
mitotic transition the recruitment process may be subtly
different. It seems likely that the long G1 phase that cells
experience upon exit from quiescence involves some re-
building of the nuclear architecture, but it remains to be
seen whether this underlies the speciﬁc requirement for
cyclin E in non-mitotic cycles.
The difference between differentiated adult cells and
cancer cells with respect to cyclin E has implications for
the functional organization of the nucleus and its relation-
ship with disease. Deregulation of cyclin E confers genome
instability (26), possibly through defects in pre-RC
assembly (27). Thus, the link between cyclin E and trans-
formation may partly reﬂect failure to correctly assemble
on the nuclear matrix, helping to support an undifferenti-
ated state.
Changes in the form and texture of the nucleus have
long been used to diagnose and classify tumours and
changes in nuclear matrix composition have been
observed in cancer cells (28). If, as we suggest, recruitment
of cyclin E to the nuclear matrix inﬂuences genome organ-
ization, possibly conferring reduced plasticity, failure to
become immobilized could have prognostic value.
However, it will be necessary to distinguish between
defects in cyclin E that impair recruitment, and wider
problems with the internal organization of the nucleus in
cancer cells.
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